OBJECTIVE: To evaluate the efficacy

safety and economical efficiency of Shuxuening injection in the treatment of ischemic stroke by the evidence-based evidence

so as to provide reference for clinical rational drug use.METHODS: Retrieved from Wanfang Data

CBM

CNKI

PubMed

the Cochrane Library

Embase

International Network of Agencies for Health Technology Assessment and Health Technology Assessment International and other websites

health technology assessment（HTA） reports

Meta-analysis/systematic reviews and pharmacoeconomic studies related to Shuxuening injection in the treatment of ischemic stroke were sorted and analyzed. The quality evaluation was performed on the literature and their methodology. RESULTS: A total of 22 literature were included

among which

10 studies were conducted on Meta-analysis/systematic reviews

12 studies were conducted on pharmacoeconomics

HTA reports were not obtained. The results of efficacy studies showed that Shuxuening injection in adjuvant treatment of ischemic stroke have certain advantages in increasing the total effective rate

improving neurological deficit score and brain CT results

laboratory indicators（whole blood viscosity

plasma viscosity

fibrinogen

erythrocyte aggregation index

hematocrit）

improving National Institutes of Health Stroke Scale score and Modified Edinburgh-Scandinavian Stroke Scale score. Safety studies showed that the adverse drug reactions of Shuxuening injection were mainly allergic-like reactions

and most of them could be resolved spontaneously after drug withdrawal. Results of pharmacoeconomic evaluation showed that Shuxuening injection did not possess economic advantages compared with Ginkgolide injection

Yinxing damo injection

Vinpocetine injection

etc.; the cost-effectiveness ratio of Shuxuening injection was better compared with Xueshuantong for injection

Acanthopanax senticosus injection

Ixeris sonchifolia injection

Edaravone injection

etc.; the results of pharmacoeconomic evaluation were inconsistent compared with Xuesaitong injection. CONCLUSIONS: Shuxuening injection in adjuvant treatment of ischemic stroke can improve clinical efficacy and improve evaluation indicators. In the future

more standardized clinical observation and related pharmacoeconomic research need to be further carried out to supplement higher-quality evidence-based evidence.